Cefotiam

Cefotiam

Clinical data
Trade names	Pansporin
AHFS/Drugs.com	International Drug Names
Routes of administration	Intravenous, intramuscular
ATC code	J01DC07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	60% (intramuscular)
Protein binding	40%
Metabolism	Nil
Elimination half-life	Approximately 1 hour
Excretion	Renal
Identifiers
IUPAC name (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)acetyl] amino}-3-{[1-(2-dimethylaminoethyl)tetrazol-5-yl] sulfanylmethyl}-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid
CAS Number	61622-34-2 Y
PubChem CID	43708
DrugBank	DB00229 Y
ChemSpider	39831 Y
UNII	91W6Z2N718
KEGG	D07648 Y
ChEBI	CHEBI:355510 Y
ChEMBL	ChEMBL1296 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H23N9O4S3
Molar mass	525.631 g/mol
3D model (JSmol)	Interactive image
SMILES CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
InChI InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1 Y Key:QYQDKDWGWDOFFU-IUODEOHRSA-N Y
(verify)

WikiDoc Resources for Cefotiam
Articles
Most recent articles on Cefotiam Most cited articles on Cefotiam Review articles on Cefotiam Articles on Cefotiam in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefotiam Images of Cefotiam Photos of Cefotiam Podcasts & MP3s on Cefotiam Videos on Cefotiam
Evidence Based Medicine
Cochrane Collaboration on Cefotiam Bandolier on Cefotiam TRIP on Cefotiam
Clinical Trials
Ongoing Trials on Cefotiam at Clinical Trials.gov Trial results on Cefotiam Clinical Trials on Cefotiam at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefotiam NICE Guidance on Cefotiam NHS PRODIGY Guidance FDA on Cefotiam CDC on Cefotiam
Books
Books on Cefotiam
News
Cefotiam in the news Be alerted to news on Cefotiam News trends on Cefotiam
Commentary
Blogs on Cefotiam
Definitions
Definitions of Cefotiam
Patient Resources / Community
Patient resources on Cefotiam Discussion groups on Cefotiam Patient Handouts on Cefotiam Directions to Hospitals Treating Cefotiam Risk calculators and risk factors for Cefotiam
Healthcare Provider Resources
Symptoms of Cefotiam Causes & Risk Factors for Cefotiam Diagnostic studies for Cefotiam Treatment of Cefotiam
Continuing Medical Education (CME)
CME Programs on Cefotiam
International
Cefotiam en Espanol Cefotiam en Francais
Business
Cefotiam in the Marketplace Patents on Cefotiam
Experimental / Informatics
List of terms related to Cefotiam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefotiam is a parenteral second-generation cephalosporin antibiotic. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria. As a beta-lactam, its bactericidal activity results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins.

Cefotiam was launched as Pansporin in February 1981 by Takeda Pharmaceutical of Japan and has been available as a generic since February 1993.

Mechanism of action

Cefotiam inhibits final cross-linking stage of peptidoglycan production, thus inhibiting bacterial cell wall synthesis. It has similar or less activity against Gram-positive staphylococci and streptococci, but is resistant to some beta-lactamases produced by Gram-negative bacteria. It is more active against many of the Enterobacteriaceae including Enterobacter, E. coli, Klebsiella, Salmonella and indole-positive Proteus species.

In clinical use, high concentrations of cefotiam are observed in several tissues (kidney, heart, ear, prostate, and genital tract), as well as in fluids and secretions (bile, ascitic fluid).

Spectrum of bacterial susceptibility

Cefotiam has a broad spectrum of activity and has been used to treat infections caused by a number of enteric bacteria and bacteria responsible for causing skin infections. The following represents MIC susceptibility data for a few medically significant bacteria.

• Bacteroides fragilis: - 16 - >128 μg/ml
• Clostridium difficile: >128 μg/ml
• Staphylococcus aureus: 0.25 - 32 μg/ml

Indications

This drug is indicated for prophylaxis for surgical infection, postoperative infections, bacterial septicaemia, bone and joint infections, cholangitis, cholecystitis, peritonitis, prostatitis, pyelonephritis, respiratory tract infections, skin and soft tissue infections, cystitis, urethritis, and infections caused by susceptible organisms. It does not have activity against Pseudomonas aeruginosa.

Dosage

For adults, the dose is up to 6 grams daily by intravenous or intramuscular route in divided doses according to severity of infection. In patients with renal impairment a dose reduction may be needed.

Adverse effects

Side effects include nausea and vomiting, diarrhoea, hypersensitivity reactions, nephrotoxicity, convulsions, CNS toxicity, hepatic dysfunction, haematologic disorders, pain at injection site, thrombophloebitis, pseudomembranous colitis, and superinfection with prolonged use.

External links

• Müller R, Böttger C, Wichmann G (2003). "Suitability of cefotiam and cefuroxime axetil for the perioperative short-term prophylaxis in tonsillectomy patients". Arzneimittelforschung. 53 (2): 126–32. doi:10.1055/s-0031-1297083. PMID 12642969.CS1 maint: Multiple names: authors list (link)
• Kolben M, Mandoki E, Ulm K, Freitag K (2001). "Randomized trial of cefotiam prophylaxis in the prevention of postoperative infectious morbidity after elective cesarean section". Eur J Clin Microbiol Infect Dis. 20 (1): 40–2. doi:10.1007/s100960000365. PMID 11245321.CS1 maint: Multiple names: authors list (link)
• Shimizu S, Chen K, Miyakawa S (1996). "Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses". Dermatology. 192 (2): 174–6. doi:10.1159/000246352. PMID 8829507.CS1 maint: Multiple names: authors list (link)